Your browser doesn't support javascript.
loading
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita, Yuka; Yagi, Yu; Kanemasa, Yusuke; Sasaki, Yuki; Ishimine, Kento; Hayashi, Yudai; Mino, Mano; Ohigashi, An; Tamura, Taichi; Nakamura, Shohei; Okuya, Toshihiro; Shimizuguchi, Takuya; Shingai, Naoki; Toya, Takashi; Shimizu, Hiroaki; Najima, Yuho; Kobayashi, Takeshi; Haraguchi, Kyoko; Doki, Noriko; Okuyama, Yoshiki; Ohashi, Kazuteru; Shimoyama, Tatsu.
Affiliation
  • Morita Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Yagi Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Kanemasa Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Sasaki Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Ishimine K; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Hayashi Y; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Mino M; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Ohigashi A; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Tamura T; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Nakamura S; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Okuya T; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Shimizuguchi T; Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Shingai N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Toya T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Shimizu H; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Najima Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Kobayashi T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Haraguchi K; Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Doki N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Okuyama Y; Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Ohashi K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Shimoyama T; Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Rinsho Ketsueki ; 64(7): 586-595, 2023.
Article in Ja | MEDLINE | ID: mdl-37544717
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Immunoconjugates / Hematopoietic Stem Cell Transplantation / Receptors, Chimeric Antigen Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: Ja Journal: Rinsho Ketsueki Year: 2023 Document type: Article Country of publication: Japón
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Immunoconjugates / Hematopoietic Stem Cell Transplantation / Receptors, Chimeric Antigen Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: Ja Journal: Rinsho Ketsueki Year: 2023 Document type: Article Country of publication: Japón